Short summary: FDA has posted Insulet’s voluntary Medical Device Correction for certain lots of Omnipod Pods because a manufacturing issue may lead to insulin under-delivery. This does not mean every Omnipod Pod is affected, but people using Omnipod should check their Pod lot numbers and have a safe backup plan if their supplies are included.
Safety note: Do not stop insulin delivery without another insulin plan or supply in place. If your Pods may be affected and you are not sure what to use, contact your diabetes team, pharmacy, or Insulet support before your insulin supply is interrupted.
Key takeaways
- The May 26, 2026 correction covers specific lots of Omnipod 5, Omnipod DASH, and Omnipod Eros Pods. It is not a blanket recall of all Omnipod products.
- The reported problem may cause insulin to leak outside the intended delivery path, which can mean less insulin reaches the body.
- Possible warning signs include wetness on the skin or Pod adhesive, smell of insulin, or unexplained high glucose readings.
- Do not stop insulin delivery without an alternative insulin method. If you are unsure what to use, contact your diabetes team or Insulet support.
What happened?
On May 26, 2026, FDA posted Insulet’s announcement of a voluntary Medical Device Correction for certain Omnipod Pods. The affected products include specific lots of Omnipod 5, Omnipod DASH, and Omnipod Insulin Management System Pods, also called Omnipod Eros.
Insulet said the issue was found through product monitoring. The concern is a manufacturing problem that may allow insulin to leak outside the intended delivery path. If that happens, less insulin may reach the body than expected.
The FDA recall database also lists a Class I recall entry for Omnipod 5 ACE Pump Pods. A Class I recall is the FDA’s most serious recall category. That database entry is specific to Omnipod 5 ACE Pump Pods and should not be stretched to every Omnipod product without checking the current notice.
Insulet’s May 26 announcement said approximately 7 million Pods were in scope worldwide and estimated that about 60% had already been used or expired. The practical point for users is still the same: check the official lot information for the Pods you have now.
Why this matters for people with diabetes
Insulin under-delivery can cause blood glucose to rise. If insulin delivery is interrupted or too low for long enough, some people can develop diabetic ketoacidosis, often called DKA. DKA is a medical emergency.
In the May 26, 2026 FDA-posted announcement, Insulet reported approximately 24 serious adverse event reports and no deaths related to this issue. That is a point-in-time report and may change if regulators or the company update the notice.
In plain language, DKA can look like nausea, vomiting, stomach pain, deep or fast breathing, fruity-smelling breath, confusion, unusual sleepiness, and very high glucose that is not improving. If DKA is suspected, urgent medical care is needed.
How to check your Pods
Use the official Omnipod or Insulet lot-number checker rather than relying on screenshots or social media lists. You may need the Pod lot number from the box, package, or supply records. If you are not sure where to find it, bring the box, Pods, or photos of the labels to your diabetes clinic, pharmacy, or device support contact. Instructions may vary by country or distributor, so international users should check the current local Omnipod or regulator notice.
Insulet’s FDA-posted notice says affected customers are being given instructions to identify affected lots, stop using impacted Pods, and obtain replacement Pods at no cost. That reflects current manufacturer instructions and may vary by country, distributor, or future update. Details can change, so check the current Insulet or regulator notice before making decisions about stored supplies.
What to do if a Pod may be affected
If a Pod is from an affected lot, follow the manufacturer’s current instructions. In general, the safety goal is to avoid using affected Pods and switch to unaffected Pods or another insulin delivery method that your care team has already approved.
If you have a temporary supply gap, do not simply go without insulin. Contact your diabetes team for backup insulin delivery instructions. This is especially important for people with type 1 diabetes and for anyone who relies on rapid-acting insulin through a pump or Pod.
Warning signs while wearing a Pod
FDA-posted materials describe signs that may include wetness around the Pod or adhesive, smell of insulin, and unexplained high glucose. The problem may not always be obvious, so glucose patterns still matter. If glucose stays high despite correction doses or usual troubleshooting, follow your sick-day or pump-failure plan and ask for urgent help when symptoms are severe.
The correction does not affect continuous glucose monitoring systems or CGM readings, according to the FDA-posted Insulet announcement. Still, CGM trends and finger-stick checks may both be useful when a reading does not match how you feel.
What this does not mean
This is not a reason to panic, and it is not a blanket warning that every Omnipod Pod is unsafe. Many Pods are not in affected lots. The practical step is to check the lot, replace affected supplies, and make sure there is a safe insulin backup if needed.
For background on pump therapy, see our guides to Omnipod 5, hybrid closed-loop systems, and insulin pump vs multiple daily injections.
Practical takeaway
If you use Omnipod, check your Pod lot numbers through the official Omnipod or Insulet correction page. Do not use affected Pods if the manufacturer says they are included, but do not stop insulin without an alternative plan. Seek urgent care if high glucose is accompanied by symptoms that could suggest DKA.
Sources
- FDA: Insulet voluntary Medical Device Correction for certain Omnipod Pods, May 26, 2026
- FDA recall database: Class 1 Device Recall Omnipod 5 ACE Pump
- Omnipod: Urgent Medical Device Correction
Editorial review note: reviewed for medical accuracy, source consistency, patient-safety framing, plain-language readability, and non-alarmist wording before publication.